Jobs — and national identity — top French concerns over the news that pharmaceutical company Sanofi plans to sell 50% of ...

The subsidiary makes household-name drugs including Doliprane branded paracetamol -- whose yellow boxes dominate the French market. Under pressure, Prime Minister Michel Barnier's minority ...

French pharmaceutical group Sanofi and US private ... Opella is best known for its emblematic brand of paracetamol, Doliprane, that holds the title as the country’s best-selling drug.

(FILES) This photograph taken on October 14, 2024 shows Doliprane, the brand under which healthcare giant Sanofi sells paracetamol, a non-opioid analgesic to ease mild to moderate pain, and of ...

Read more French government stuck in Doliprane dilemma A series of guarantees have been listed in this agreement. The first concerns the future of the Lisieux and Compiègne (north of Paris ...

The scope for meddling with Opella was always going to be high, as my colleague Chris Hughes flagged, given its manufacture of paracetamol brand Doliprane, a fixture in French bathroom cabinets.

But Sanofi, one of the world's 12 largest pharmaceutical companies, had not counted on how attached the French are to Doliprane, whose yellow boxes occupy shelf after shelf in French pharmacies ...

Doliprane, at €16 billion. "Sanofi and CD&R announce today a plan to join forces to fuel Opella's ambitions as a French-headquartered, global consumer healthcare champion," it said Monday ...

Minhtu Phan joined dozens of teachers at a French-language adult education centre in Quebec City on Friday morning as he held up a sign objecting to cutting French-language classes across the ...

"Doliprane must stay in France. It belongs to the French," CFDT union coordinator and Sanofi production technician Adil Bensetra said outside the Compiegne plant in northern France during Thursday ...

Opella generates annual revenues of 5.2 billion euros and employs 11,000 people globally, French newspaper Le Figaro said. Sanofi, France's biggest pharmaceutical group, said last week that it was ...

Souveraineté sanitaire et industrielle, perte d’emplois, rentabilité à court terme… Les polémiques sont nombreuses depuis l’annonce de Sanofi de sa séparation avec sa filiale “grand public” Opella qui ...